Highlights

• The top ASX digital health stocks July 2026 theme brings together five contrasting health-technology platforms spanning AI imaging, clinical analytics, radiology workflow, hospital patient engagement and medical visualisation software.

• Artrya (ASX:AYA), Beamtree (ASX:BMT), ImExHS (ASX:IME), Oneview Healthcare (ASX:ONE) and Pro Medicus (ASX:PME) each sit at a different point on the maturity curve, from earlier-stage commercialisation to an established software leader.

• The shared narrative is healthcare digitisation: recurring subscription and transaction revenue, clinical decision support, and software embedded into radiology and hospital workflows.

• Software economics — high gross margins, scalable licences and sticky contracts — sit alongside valuation risk that can leave little room for disappointment.

• Common risks include customer concentration, long hospital procurement and sales cycles, global expansion execution, regulatory clearance timelines and intensifying competition.

• Healthcare is often viewed as relatively defensive, yet health-tech growth names can behave more like technology stocks and remain sensitive to sentiment and rates.

• Dividend appeal is limited across most of the group, as many names reinvest heavily for growth rather than distribute income.

The top ASX digital health stocks July 2026 conversation is increasingly a conversation about software. As Australia’s healthcare system leans harder into digitisation, the companies drawing attention are less about bricks-and-mortar facilities and more about the code, data and clinical intelligence that run inside them. Five ASX-listed health-technology names sit within that software lens: Artrya Ltd (ASX:AYA) in AI-assisted cardiac imaging, Beamtree Holdings Ltd (ASX:BMT) in clinical analytics and decision support, ImExHS Ltd (ASX:IME) in cloud radiology workflow, Oneview Healthcare PLC (ASX:ONE) in hospital patient engagement, and Pro Medicus Ltd (ASX:PME) in medical imaging visualisation.

These five businesses are not competitors in any neat sense. They occupy separate niches within the broader healthcare-technology stack, and they differ enormously in scale, profitability and maturity. What unites them is a structural story: hospitals, radiology practices and health systems are digitising, and software that improves diagnosis, workflow and patient experience sits close to the centre of that shift.

Why This ASX Healthcare Theme Is in Focus in July 2026

Digital health has moved from a fringe idea to a mainstream investment theme. Artificial intelligence has become the dominant lens through which markets assess technology businesses, and healthcare is one of the fields where its practical, clinically validated applications are most visible, from image analysis to decision support.

The second reason is the enduring pressure on health systems worldwide: ageing populations, workforce shortages, rising chronic disease and constrained budgets are structural forces that do not fade with the economic cycle, and software that helps clinicians do more with less speaks directly to those pressures.

The third reason is the quality of the underlying business models — recurring revenue, high gross margins and sticky customer relationships once a platform is embedded in a workflow. The counterweight is valuation: when a market embraces a theme, prices can run ahead of demonstrated earnings, and that tension between software quality and demanding expectations is the defining feature of this watchlist.

Australian Healthcare Sector Backdrop

Australia’s healthcare sector is large, diverse and structurally supported by long-run demographic trends, spanning hospitals, pathology, imaging, medical devices, biotechnology, aged care and a growing layer of health-technology providers. Ageing underpins demand for diagnostic imaging, cardiac care and chronic-disease management, while a persistent workforce challenge among radiologists, cardiologists and nurses means software that improves productivity addresses the squeeze directly. Funding is the other defining feature: Medicare, private health insurance and hospital budgets shape reimbursement and procurement, meaning the path to revenue for health-tech companies often runs through institutions with careful purchasing processes. For the software names in this article, the Australian market is frequently a base rather than the whole opportunity, since radiology software, imaging visualisation and clinical analytics are global markets carrying their own currency, competitive and regulatory considerations.

Within healthcare, traditional providers deliver care and generate clinical data, while digital health sits on top, turning that activity into software-enabled workflows and decision support. A software provider earns revenue by licensing its platform and can scale it to additional customers at relatively low incremental cost, which is why the market often applies different valuation frameworks to health-tech names than to health-services operators. Clinical data is valuable, sensitive and tightly regulated, so companies that aggregate and analyse it must meet strict privacy, security and clinical-governance standards, where any failure can carry reputational and financial consequences.

Company Analysis

Artrya (ASX:AYA)

Artrya is a medical-technology company focused on cardiac imaging, using artificial intelligence to assist the analysis of coronary arteries and support faster, more consistent clinical interpretation. Its growth angle rests on clinical validation, regulatory clearances in target markets, and translating those clearances into commercial adoption. As an earlier-stage business, it may not yet generate the scale of recurring revenue seen at more mature peers, meaning reliance on capital and sensitivity to funding conditions. Regulatory timelines are uncertain, commercial adoption in healthcare is often slow, and competition in AI-assisted imaging is intensifying.

Beamtree (ASX:BMT)

Beamtree operates in clinical analytics, healthcare data and decision support, helping health systems use the data they generate through products supporting coding, clinical documentation and benchmarking. Its growth angle combines organic expansion, international reach and layering AI and knowledge-based capabilities onto its data assets. Risks include long health-system sales cycles, customer concentration, execution risk across diverse international regulatory regimes, and competition from other analytics providers and AI-focused entrants.

ImExHS (ASX:IME)

ImExHS provides medical imaging and radiology workflow software, including RIS and PACS systems, increasingly delivered through the cloud to imaging providers and health systems. Its growth angle rests on expanding cloud and recurring revenue, cross-selling additional modules and extending its footprint across regions including Latin America. Risks include competitive intensity in imaging software, lengthy sales and implementation cycles, currency and country-specific exposure, and sensitivity to funding conditions as a smaller-capitalisation company.

Oneview Healthcare (ASX:ONE)

Oneview Healthcare provides a hospital patient-engagement platform delivered at the bedside, giving patients digital access to entertainment, education and communication during a hospital stay. Its growth angle centres on winning hospital contracts, expanding within existing customers and growing recurring software revenue. Risks include slow hospital procurement, discretionary budget treatment of patient-engagement technology, customer concentration given the size of individual contracts, and the path to consistent profitability.

Pro Medicus (ASX:PME)

Pro Medicus is the most established of the five, known for its Visage platform delivering advanced radiology visualisation and enterprise imaging, used by major health systems particularly in the United States. Its growth angle rests on continued penetration of the North American market, new contract wins, renewals and product extension including AI-enabled capabilities. The central risk is valuation: a premium multiple leaves limited room for disappointment, and any slowdown in contract momentum or margin pressure could weigh heavily on sentiment given how much optimism is embedded in the price.

Comparative View: How the Stocks Differ

Placed side by side, the five names span much of the health-tech investment spectrum. Pro Medicus sits at one end as a mature, profitable, cash-generative leader trading on a premium multiple. Beamtree and ImExHS occupy a middle ground as smaller, growth-focused businesses building recurring revenue. Oneview Healthcare is a specialist in patient engagement with a distinctive product focus, while Artrya sits at the earlier-stage, higher-risk end where regulatory and commercial milestones dominate the outlook. They differ by clinical focus, revenue model, profitability, and geography — Pro Medicus is heavily US-oriented, ImExHS spans Latin America and beyond — meaning currency exposure, competitive dynamics and risk profile all vary. These are not interchangeable names; each demands its own analysis.

Key Growth Themes Across the Group

• Healthcare digitisation: health systems are steadily replacing manual and legacy processes with software across imaging, analytics and patient engagement.

• AI in healthcare: coronary analysis, imaging workflow enhancements and clinical decision support are increasingly woven into the value proposition of each name.

• Recurring revenue and software economics: subscription, licence and transaction-based models can deliver predictable revenue, high margins and strong retention once embedded.

• The productivity imperative from workforce shortages: software that helps clinicians do more with constrained resources speaks to a structural need.

• Globalisation: radiology software, imaging visualisation and clinical analytics are global markets, and several companies pursue international growth.

Risks Investors Should Watch

• Valuation: premium multiples on higher-quality names leave little room for disappointment and can de-rate sharply if growth slows.

• Customer concentration: reliance on a limited number of large contracts can make revenue lumpy.

• Long sales and procurement cycles typical of healthcare, where deals can slip or be deferred in constrained budget environments.

• Global-expansion execution, currency exposure and differing regulatory regimes across markets.

• Regulatory clearance timelines, and ongoing privacy, data-protection and cybersecurity obligations.

• Intensifying competition across every niche, from AI imaging to enterprise radiology to clinical analytics.

• Funding and profitability risk for earlier-stage names, where capital raisings can dilute shareholders.

• Sentiment sensitivity: health-tech growth stocks can behave like broader technology stocks, moving with interest rates and risk appetite.

What Could Drive These Stocks Next

Contract announcements are among the most direct catalysts, particularly for Pro Medicus and Oneview Healthcare, where major health-system wins can be significant relative to size. For Beamtree and ImExHS, evidence of accelerating recurring revenue and margin improvement could support growth narratives. Regulatory progress is a key driver for Artrya, where clearances in target markets could unlock commercial opportunity. Across the group, demonstrable progress in AI capabilities, improvements in profitability and cash generation, and successful international expansion could all matter, alongside broader interest-rate settings, market sentiment and healthcare policy developments.

Conclusion

The top ASX digital health stocks July 2026 theme captures one of the more compelling structural stories on the market: the digitisation of healthcare, powered by AI, recurring-revenue software and the enduring pressures of ageing populations and workforce shortages. Artrya (ASX:AYA), Beamtree Holdings (ASX:BMT), ImExHS (ASX:IME), Oneview Healthcare (ASX:ONE) and Pro Medicus (ASX:PME) each offer a distinct window into that story, spanning AI cardiac imaging, clinical analytics, radiology workflow, hospital patient engagement and medical imaging visualisation. Yet the theme is defined as much by its risks as its opportunities — rich valuations, customer concentration, long sales cycles, global-expansion complexity, regulatory hurdles and intensifying competition are real, and health-tech growth shares can be volatile despite healthcare’s defensive reputation. These five names are best viewed as a spectrum of risk and maturity, each warranting individual analysis rather than treatment as a single basket.

()